Description

Molecular diagnostics in genetic testing brings advanced analytical techniques to the diagnosis and treatment of genetic disorders. The confluence of breakthroughs in genomics and proteomics and the development of microarray devices to measure analytes in the blood and various body tissues are driving significant growth in the segment. Major developments include the integration of specialty labs and gene expression profiling into clinical practice, the introduction and rapid growth of cell-free fetal DNA prenatal testing, the advancement of companion diagnostics for drug development, the widespread installed base of automated instruments for molecular testing and the development of personalized medicine. The genetic testing space is one of the most profitable sectors of molecular diagnostics and is expected to be an area of high growth and corporate change throughout the forecast period. This TriMark Publications report describes the emerging field of molecular diagnostics in genetic testing. This review analyzes the size and growth of the molecular diagnostics in genetic testing market, including the factors that influence the various market segments within it and the dollar volume of sales, both in the United States and worldwide. Moreover, this analysis profiles the leading companies focused on the molecular diagnostics for genetic testing sector.

8. Business Decisions, Strategic Outlook and Recommendations Using Molecular Diagnostic Tests in Genetic Testing 155 8.1 Key Opportunities in Genetic Testing Development and Commercialization 155 8.2 What are the Current Obstacles in Molecular Diagnostic Genetic Testing Implementation? 155 8.3 How are Genetic Testing Products Driven by Business Strategies? 156 8.4 How might Novel Genetic Test Development Lead to Acquisition Strategies? 156 8.5 How can Genetic Tests Increase Value in Associated Drug Marketing Plans? 157 8.6 What Steps can be Taken in the Clinical Phases to Improve the Success Rate of Genetic Tests in Development? 157 8.7 How can Regulatory Oversight Drive Approval and Adoption of New Technologies? 157 8.8 What are the Noteworthy Deals? 158 8.9 How will Platform Technology Companies Enter the Space and Position Themselves for Diagnostic Development? 159 8.10 Will Pharma Integrate with Diagnostics? 159 8.11 How will Partnering and M&As Alter the Competitive Landscape? 160 8.12 How will FDA Regulations Impact New Diagnostic Tests? 160 8.13 What is Necessary for Incorporating Promising Molecular Tests into Clinical Practice 161 8.14 What is the Best Type of Business Model for Developing Genetic Testing Biomarkers? 162 8.15 How have Genetic Biomarkers Provided the Most Benefit in Genetic Testing? 163 8.16 What are the Most Innovative Methods in Development of Molecular Diagnostic Biomarkers? 163